1. Home
  2. MNDY vs VTRS Comparison

MNDY vs VTRS Comparison

Compare MNDY & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MNDY
  • VTRS
  • Stock Information
  • Founded
  • MNDY 2012
  • VTRS 1961
  • Country
  • MNDY Israel
  • VTRS United States
  • Employees
  • MNDY N/A
  • VTRS N/A
  • Industry
  • MNDY Computer Software: Prepackaged Software
  • VTRS Medicinal Chemicals and Botanical Products
  • Sector
  • MNDY Technology
  • VTRS Health Care
  • Exchange
  • MNDY Nasdaq
  • VTRS Nasdaq
  • Market Cap
  • MNDY 9.5B
  • VTRS 11.1B
  • IPO Year
  • MNDY 2021
  • VTRS N/A
  • Fundamental
  • Price
  • MNDY $195.94
  • VTRS $10.27
  • Analyst Decision
  • MNDY Strong Buy
  • VTRS Hold
  • Analyst Count
  • MNDY 21
  • VTRS 6
  • Target Price
  • MNDY $298.19
  • VTRS $11.17
  • AVG Volume (30 Days)
  • MNDY 1.0M
  • VTRS 6.9M
  • Earning Date
  • MNDY 11-10-2025
  • VTRS 11-06-2025
  • Dividend Yield
  • MNDY N/A
  • VTRS 4.67%
  • EPS Growth
  • MNDY N/A
  • VTRS N/A
  • EPS
  • MNDY 0.76
  • VTRS N/A
  • Revenue
  • MNDY $1,100,240,000.00
  • VTRS $14,115,700,000.00
  • Revenue This Year
  • MNDY $28.70
  • VTRS N/A
  • Revenue Next Year
  • MNDY $22.30
  • VTRS $1.61
  • P/E Ratio
  • MNDY $262.97
  • VTRS N/A
  • Revenue Growth
  • MNDY 30.24
  • VTRS N/A
  • 52 Week Low
  • MNDY $166.22
  • VTRS $6.85
  • 52 Week High
  • MNDY $342.64
  • VTRS $13.55
  • Technical
  • Relative Strength Index (RSI)
  • MNDY 55.07
  • VTRS 54.35
  • Support Level
  • MNDY $176.00
  • VTRS $10.18
  • Resistance Level
  • MNDY $202.31
  • VTRS $10.46
  • Average True Range (ATR)
  • MNDY 6.53
  • VTRS 0.20
  • MACD
  • MNDY 2.25
  • VTRS 0.02
  • Stochastic Oscillator
  • MNDY 85.52
  • VTRS 65.45

About MNDY monday.com Ltd.

Monday.com is a work management platform allowing for increased collaboration and visibility across an organization. Delivered via a SaaS-based model, users can track progress across marketing and development initiatives, create and automate workflows, and manage IT approvals. Revenue is generated on a per-seat basis across several pricing tiers. As of fiscal 2024, the company had over 245,000 customers.

About VTRS Viatris Inc.

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Share on Social Networks: